About the Journal

Overview

Clinical & Experimental Immunology (CEI) is an authoritative, international and well-respected journal publishing high-quality and impactful research and review articles in the field of translational immunology. The journal is brought to you by the British Society for Immunology.

All primary research papers published in Clinical & Experimental Immunology are:

• Relevant to human disease

• Based (in part) on translational research

• Underpinned by novel mechanistic insight

Impact Factor: 3.4 (ranked 93/181)*
5-year Impact Factor: 4.1*
Immediacy Index: 0.8*
Citescore: 8.4 (ranked 63/233)

*Source: Journal Citation Reports™ from Clarivate, 2024.

Aims and scope

Clinical & Experimental Immunology has published research at the cutting edge of translational and clinical immunology since 1966. We are interested in studies that have the potential to transform our understanding of the immunopathology of human disease and/or change clinical practice. 

The journal is among the foremost journals in the field of translational and clinical immunology, attracting high-quality papers from across the world. Translation is viewed as a process of applying ideas, insights and discoveries generated through scientific studies to the treatment, prevention or diagnosis of human disease. Clinical immunology has evolved as a field to encompass the application of state-of-the-art technologies such as next-generation sequencing, metagenomics and high-dimensional phenotyping to understand the mechanisms that govern the outcomes of clinical trials.

Journal articles are received by our dedicated Section Editors and cover basic and clinical investigations into the immunological basis of a wide range of human pathologies including autoimmunity, inflammatory diseases, primary and secondary immunodeficiencies, complement disorders, allergies, infectious diseases, cancer and transplantation rejection. Research that offers mechanistic insight is particularly encouraged. Studies that inform clinical practice and those that represent position papers on the classification, diagnosis or treatment of immunological disease are also welcomed.

Any paper which does not fit into one of the sections described below will be assessed by our Editor-in-Chief. All papers with high relevance to translational immunology are welcome.
 
Clinical & Experimental Immunology is part of the British Society for Immunology family of journals, including our sibling journal Immunotherapy Advances.

Journal Sections

Led by Editor-in-Chief Professor Claudia Mauri, King's College London, UK, the journal has dedicated sections including:

Autoimmunity

Hellesen (et al.) (https://doi.org/10.1111/cei.13207)

Led by Angelo Manfredi of Università Vita-Salute San Raffaele, Milan

• Insights into the mechanisms underlying the onset, remission and relapse of autoimmune diseases.

• Studies that report new therapies and biomarkers that reflect relevant pathogenetic events.

• Experimental autoimmune diseases as a tool to understand the complexity of human autoimmunity.

• Identification of the characteristics that will inform our understanding of autoimmunity and eventually improve the nosology, stratification and patient care.

• Figure Credit: Hellesen (et al.) (https://doi.org/10.1111/cei.13207)

Hellesen (et al.) (https://doi.org/10.1111/cei.13207)

Cancer Immunity

Led by Tanja de Gruijl, VUmc Amsterdam, Netherlands

• Studies on (neo)adjuvant immunotherapy strategies, including immune checkpoint blockade, adoptive cell transfer, vaccination, oncolytic virotherapy, adjuvants, bispecific targeting and immune modulation approaches.

• Immune monitoring and profiling studies of tumour conditioned microenvironments or systemic immunity, and the identification of (immune) biomarkers/signatures with predictive or prognostic value.

• Studies providing novel mechanistic insights into immune control or escape of tumours, including studies on immune suppression, immunotherapy resistance, the role of the microbiome, metabolism, and epigenetics.

Harjunpää (et al.) (https://doi.org/10.1111/cei.13407)

Immune-mediated Inflammatory Diseases

Led by Ciriaco Piccirillo of McGill University, Canada

• Detailed characterisation of the immune environment in human inflamed tissue, underpinned by mechanistic insight.

• Application of cutting-edge technologies to advance the understanding of inflammation, its causes and consequences.

• In vitro or in situ investigation of the cross-talk of the immune system with non-hematopoietic cells or systems.

Wehmeyer (et al.) (https://doi.org/10.1111/cei.12979)

Immunodeficiency

Led by Cindy Ma of the Garvan Institute of Medical Research, Australia

• Insights into the mechanisms and causes of primary and secondary immunodeficiencies.

• Identification of novel genetic defects, mutations or external factors which cause immunodeficiencies.

• New insights into the molecular or cellular basis of immunodeficiency-related syndromes.

• Application of new technologies to advance the understanding and treatment of immunodeficiency-related syndromes.

• The use of novel therapeutics to treat immunodeficiencies.

Kienzler (et al.) (https://doi.org/10.1111/cei.12947)

Infectious Diseases and Vaccines

Led by Danny Douek, National Institute of Allergy and Infectious Diseases/National Institutes of Health/DHHS, USA, and Xiao-Ning Xu, Imperial College London, UK

• Studies of vaccines in humans or preclinical animal models with a short time frame for translation into humans.

• Biomarkers that correlate with clinical outcome in infectious diseases.

• Host/pathogen relationships including host genetic determinants of susceptibility to infections.

• Emerging infectious diseases.

• Studies on the microbiome, therapeutic microbial manipulation, and anti-microbial resistance.

Williamson (et al.) (https://doi.org/10.1111/cei.13284)

Neuroimmunology

Led by Sandra Amor, VUmc Amsterdam, Netherlands

• Human or model systems that provide insights into the pathogenesis of immune-mediated diseases of the central and peripheral nervous systems.

• Cellular/molecular studies that expand the understanding of neuroimmune diseases.

• Proof-of-concept studies and preclinical trials of novel therapeutic approaches for neuroimmune diseases.

• Biomarkers that correlate with clinical outcome in neuroimmune diseases.

• Cutting-edge technologies to image neuroinflammation and aid the understanding of disease.

Bennett (et al.) (https://doi.org/10.1111/cei.13334)

Clinical & Experimental Immunology is also interested in articles in the following subject areas. These articles will be handled by one of our Section Editors.

Allergy, Asthma and Respiratory Immunology

Areas of interest include:

• Studies that provide immunological insight into the development, treatment or diagnosis of respiratory disease or allergy.

• Translational or clinical studies that report on immunological responses to respiratory diseases or allergies.

• Technologies or models that advance the immunological understanding of respiratory disease, asthma, and allergy.

• Investigations into infections that affect the respiratory system, including but not limited to SARS-CoV-2.

Boe (et al.) (https://doi.org/10.1111/cei.12881)

Immunity and Ageing

Areas of interest include: 

• Studies describing age-related changes in immunity, as well as the testing of interventions to reverse these changes.

• Molecular mechanisms underlying age-related immune dysfunction.

• New strategies and technologies to counteract the age-related changes in immune response to disease and infection.

Nasi (et al.) (https://doi.org/10.1111/cei.12814)

The journal is also interested in articles covering all other areas of clinical and translational immunology, including; transplantation, immune regulation & recognition, immunometabolism, innate immunity and mucosal immunology.

In addition to primary research, Clinical & Experimental Immunology publishes highly-cited review articles. These are usually commissioned and published as review series, but suggestions to the Editor-in-Chief of topics for such series or titles for one-off review articles are welcome.

If you would like to submit an article to Clinical & Experimental Immunology, please visit our submission site page.

Abstracting and Indexing Information

• Abstracts in Anthropology (Sage)

• Abstracts on Hygiene & Communicable Diseases (CABI)

• Academic Search (EBSCO Publishing)

• Academic Search Alumni Edition (EBSCO Publishing)

• Academic Search Elite (EBSCO Publishing)

• Academic Search Premier (EBSCO Publishing)

• AGRICOLA Database (National Agricultural Library)

• Agricultural & Environmental Science Database (ProQuest)

• BIOBASE: Current Awareness in Biological Sciences (Elsevier)

• Biological Abstracts (Clarivate Analytics)

• Biological Science Database (ProQuest)

• BIOSIS Previews (Clarivate Analytics)

• CAB Abstracts® (CABI)

• CAS: Chemical Abstracts Service (ACS)

• Current Contents: Clinical Medicine (Clarivate Analytics)

• Embase (Elsevier)

• Health Source Nursing/Academic (EBSCO Publishing)

• HEED: Health Economic Evaluations Database (Wiley-Blackwell)

• Journal Citation Reports/Science Edition (Clarivate Analytics)

• MEDLINE/PubMed (NLM)

• Natural Science Collection (ProQuest)

• Proquest Pharma Collection (ProQuest)

• PubMed Dietary Supplement Subset (NLM)

• PubMed via PMC deposit (NLM)

• Science Citation Index (Clarivate Analytics)

• Science Citation Index Expanded (Clarivate Analytics)

• SciTech Premium Collection (ProQuest)

• VINITI (All-Russian Institute of Science & Technological Information)